| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
Departments of Pathology [M. A., L. C., W. L. G.], Pediatrics [J. M., N-K. V. C.], and Epidemiology and Biostatistics [A. S., J. Q.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021
Molecular mechanisms through which MYCN expression contributes to the malignant phenotype of neuroblastoma are unknown.We performed a genome-widegene expression analysis of 40 well-characterized neuroblastic tumors and 12 cell lines to identify genes and biological pathways associated with MYCN expression. Gene expression was validated by reverse transcription-PCR and immunohistochemistry using tissue arrays. Two hundred twenty-two of 62,839 oligonucleotide probe sets detected expression of genes that were strongly associated with MYCN expression. Differentially expressed genes included examples of known oncogenes, genes associated with neural differentiation, and genes related to cell proliferation. Expression of a subset of these genes was altered after transfection of a neuroblastoma cell line, SK-N-ER, with a MYCN expressing gene construct when protein synthesis was inhibited and have consensus MYCN binding E-box sequences in their promotor regions, suggesting they represent direct targets. Several novel genes/expressed sequences were identified as overexpressed and most likely coamplified with MYCN in a subset of cases. A classification model to identify neuroblastomas with high levels of MYCN expression was developed based on expression profiles. The identification of coexpressed and coamplified genes associated with MYCN overexpression in neuroblastoma suggests biochemical pathways that contribute to the malignant behavior of these tumors and forms a basis for molecular classification.
This article has been cited by other articles:
![]() |
M. Ladanyi William L. Gerald, M.D., Ph.D, 1954-2008 J. Mol. Diagn., January 1, 2009; 11(1): 1 - 3. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Y. Cheung, Y. Feng, W. Gerald, and N.-K. V. Cheung Exploiting Gene Expression Profiling to Identify Novel Minimal Residual Disease Markers of Neuroblastoma Clin. Cancer Res., November 1, 2008; 14(21): 7020 - 7027. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Stock, E. Bozsaky, F. Watzinger, U. Poetschger, L. Orel, T. Lion, A. Kowalska, and P. F. Ambros Genes Proximal and Distal to MYCN Are Highly Expressed in Human Neuroblastoma as Visualized by Comparative Expressed Sequence Hybridization Am. J. Pathol., January 1, 2008; 172(1): 203 - 214. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Voth, A. Oberthuer, T. Simon, Y. Kahlert, F. Berthold, and M. Fischer Identification of DEIN, a Novel Gene with High Expression Levels in Stage IVS Neuroblastoma Mol. Cancer Res., December 1, 2007; 5(12): 1276 - 1284. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Westermann, K.-O. Henrich, J. S. Wei, W. Lutz, M. Fischer, R. Konig, R. Wiedemeyer, V. Ehemann, B. Brors, K. Ernestus, et al. High Skp2 Expression Characterizes High-Risk Neuroblastomas Independent of MYCN Status Clin. Cancer Res., August 15, 2007; 13(16): 4695 - 4703. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Oppenheimer, N.-K. Cheung, and W. L. Gerald The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma Mol. Cancer Ther., April 1, 2007; 6(4): 1300 - 1309. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fischer, A. Oberthuer, B. Brors, Y. Kahlert, M. Skowron, H. Voth, P. Warnat, K. Ernestus, B. Hero, and F. Berthold Differential Expression of Neuronal Genes Defines Subtypes of Disseminated Neuroblastoma with Favorable and Unfavorable Outcome Clin. Cancer Res., September 1, 2006; 12(17): 5118 - 5128. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Wang, S. Diskin, E. Rappaport, E. Attiyeh, Y. Mosse, D. Shue, E. Seiser, J. Jagannathan, S. Shusterman, M. Bansal, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res., June 15, 2006; 66(12): 6050 - 6062. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Giannini, F. Cerignoli, M. Mellone, I. Massimi, C. Ambrosi, C. Rinaldi, C. Dominici, L. Frati, I. Screpanti, and A. Gulino High Mobility Group A1 Is a Molecular Target for MYCN in Human Neuroblastoma Cancer Res., September 15, 2005; 65(18): 8308 - 8316. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Alaminos, V. Davalos, S. Ropero, F. Setien, M. F. Paz, M. Herranz, M. F. Fraga, J. Mora, N.-K. V. Cheung, W. L. Gerald, et al. EMP3, a Myelin-Related Gene Located in the Critical 19q13.3 Region, Is Epigenetically Silenced and Exhibits Features of a Candidate Tumor Suppressor in Glioma and Neuroblastoma Cancer Res., April 1, 2005; 65(7): 2565 - 2571. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fischer, M. Skowron, and F. Berthold Reliable Transcript Quantification by Real-Time Reverse Transcriptase-Polymerase Chain Reaction in Primary Neuroblastoma Using Normalization to Averaged Expression Levels of the Control Genes HPRT1 and SDHA J. Mol. Diagn., February 1, 2005; 7(1): 89 - 96. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Uccini, O. Mannarino, H. P. McDowell, U. Pauser, R. Vitali, P. G. Natali, P. Altavista, T. Andreano, S. Coco, R. Boldrini, et al. Clinical and Molecular Evidence for c-kit Receptor as a Therapeutic Target in Neuroblastic Tumors Clin. Cancer Res., January 1, 2005; 11(1): 380 - 389. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. McArdle, M. McDermott, R. Purcell, D. Grehan, A. O'Meara, F. Breatnach, D. Catchpoole, A. C. Culhane, I. Jeffery, W. M. Gallagher, et al. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q Carcinogenesis, September 1, 2004; 25(9): 1599 - 1609. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Alaminos, V. Davalos, N.-K. V. Cheung, W. L. Gerald, and M. Esteller Clustering of Gene Hypermethylation Associated With Clinical Risk Groups in Neuroblastoma J Natl Cancer Inst, August 18, 2004; 96(16): 1208 - 1219. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |